Clinical Trial Update: Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating ixabepilone in relapsed/refractory advanced ovarian epithelial or primary peritoneal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Ixabepilone (ixabepilone)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Ovarian Cancer, Peritoneal Cavity Cancer | Phase 2 | Status: COMPLETED